PMID- 37600670
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230823
IS  - 1179-1314 (Print)
IS  - 1179-1314 (Electronic)
IS  - 1179-1314 (Linking)
VI  - 15
DP  - 2023
TI  - HER2-Low Breast Cancer: Current Landscape and Future Prospects.
PG  - 605-616
LID - 10.2147/BCTT.S366122 [doi]
AB  - More than 50% of breast cancers are currently defined as "Human epidermal growth 
      factor receptor 2 (HER2) low breast cancer (BC)", with HER2 immunohistochemistry 
      (IHC) scores of +1 or +2 with a negative fluorescence in situ hybridization 
      (FISH) test. In most studies that compared the clinical and biological 
      characteristics of HER2-low BC with HER2-negative BC, HER2-low was not associated 
      with unique clinical and molecular characteristics, and it seems that the 
      importance of HER2 in these tumors is being a docking site for the antibody 
      portion of antibody drug conjugates (ADCs). Current pathological methods may 
      underestimate the proportion of BCs that express low levels of HER2 due to 
      analytical limitations and tumor heterogeneity. In this review we summarize and 
      contextualize the most recent literature on HER2-low breast cancers, including 
      clinical and translational studies We also review the challenges of assessing low 
      HER2 expression in BC and discuss the current and future therapeutic landscape 
      for these tumors.
CI  - (c) 2023 Shirman et al.
FAU - Shirman, Yelena
AU  - Shirman Y
AD  - Division of Oncology, Rambam Health Care Campus, Haifa, Israel.
FAU - Lubovsky, Shlomit
AU  - Lubovsky S
AD  - Division of Oncology, Rambam Health Care Campus, Haifa, Israel.
FAU - Shai, Ayelet
AU  - Shai A
AD  - Division of Oncology, Rambam Health Care Campus, Haifa, Israel.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230814
PL  - New Zealand
TA  - Breast Cancer (Dove Med Press)
JT  - Breast cancer (Dove Medical Press)
JID - 101591856
PMC - PMC10439285
OTO - NOTNLM
OT  - ERBB2 low
OT  - HER2 targeted therapy
OT  - HER2-low
OT  - T-DXd
OT  - breast cancer
OT  - trastuzumab
OT  - trastuzumab-deruxtecan
COIS- AS reports receiving travel funds and honoraria from AstraZeneca. YS and SL 
      report no conflicts of interest in this work.
EDAT- 2023/08/21 06:42
MHDA- 2023/08/21 06:43
PMCR- 2023/08/14
CRDT- 2023/08/21 04:48
PHST- 2023/04/08 00:00 [received]
PHST- 2023/08/09 00:00 [accepted]
PHST- 2023/08/21 06:43 [medline]
PHST- 2023/08/21 06:42 [pubmed]
PHST- 2023/08/21 04:48 [entrez]
PHST- 2023/08/14 00:00 [pmc-release]
AID - 366122 [pii]
AID - 10.2147/BCTT.S366122 [doi]
PST - epublish
SO  - Breast Cancer (Dove Med Press). 2023 Aug 14;15:605-616. doi: 
      10.2147/BCTT.S366122. eCollection 2023.